Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 24;7(2):37.
doi: 10.3390/vaccines7020037.

A Comparison of Plasmid DNA and mRNA as Vaccine Technologies

Margaret A Liu  1
Affiliations
Review

A Comparison of Plasmid DNA and mRNA as Vaccine Technologies

Margaret A Liu. Vaccines (Basel). .

Abstract

This review provides a comparison of the theoretical issues and experimental findings for plasmid DNA and mRNA vaccine technologies. While both have been under development since the 1990s, in recent years, significant excitement has turned to mRNA despite the licensure of several veterinary DNA vaccines. Both have required efforts to increase their potency either via manipulating the plasmid DNA and the mRNA directly or through the addition of adjuvants or immunomodulators as well as delivery systems and formulations. The greater inherent inflammatory nature of the mRNA vaccines is discussed for both its potential immunological utility for vaccines and for the potential toxicity. The status of the clinical trials of mRNA vaccines is described along with a comparison to DNA vaccines, specifically the immunogenicity of both licensed veterinary DNA vaccines and select DNA vaccine candidates in human clinical trials.

Keywords: Cytolytic T Lymphocytes; DNA vaccine; antibodies; formulations; immune responses; in vitro transcribed mRNA; innate immunity; mRNA vaccine; plasmid DNA.

PubMed Disclaimer

Conflict of interest statement

“The author declares no conflict of interest.”

References

    1. Liu M.A. DNA vaccines: An historical perspective and view to the future. Immunol. Rev. 2011;239:62–84. doi: 10.1111/j.1600-065X.2010.00980.x. - DOI - PubMed
    1. Pardi N., Hogan M.J., Porter F.W., Weissman D. mRNA vaccines––A new era in vaccinology. Nat. Rev. Drug Discov. 2018;17:261–279. doi: 10.1038/nrd.2017.243. - DOI - PMC - PubMed
    1. Stevenson F.K., Zhu D., King C.A., Ashworth L.J., Kumar S., Hawkins R.E. Idiotypic DNA vaccines against B-cell lymphoma. Immunol. Rev. 1995;145:211–228. doi: 10.1111/j.1600-065X.1995.tb00083.x. - DOI - PubMed
    1. Syrengelas A.D., Chen T.T., Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat. Med. 1996;2:1038–1041. doi: 10.1038/nm0996-1038. - DOI - PubMed
    1. Sahin U., Karikó K., Türeci Ö. mRNA-based therapeutics––Developing a new class of drugs. Nat. Rev. Drug Discov. 2014;13:759–780. doi: 10.1038/nrd4278. - DOI - PubMed

LinkOut - more resources